Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer

Rachel A. Freedman, MD, MPH
Published: Thursday, Jun 29, 2017



Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.

Targeting dual anti-HER2 targeting therapy is attractive, says Freedman, especially ONT-380, which does not have as many adverse events as seen with therapies such as neratinib (Nerlynx).
 
SELECTED
LANGUAGE


Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.

Targeting dual anti-HER2 targeting therapy is attractive, says Freedman, especially ONT-380, which does not have as many adverse events as seen with therapies such as neratinib (Nerlynx).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x